: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

The Angels Initiative

Stroke prevention

Lung Cancer

Free Subscription

Articles published in BMC Cancer
Retrieve available abstracts of 338 articles:
HTML format

Single Articles

March 2023

HAYASHI K, Suzuki O, Shiomi H, Ono H, et al
Stereotactic ablative body radiotherapy with a central high dose using CyberKnife for metastatic lung tumors.
BMC Cancer. 2023;23:215.
PubMed Abstract available

ZHEN H, Tian J, Li G, Zhao P, et al
Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis.
BMC Cancer. 2023;23:207.
PubMed Abstract available

XU Z, Hao X, Wang Q, Yang K, et al
Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.
BMC Cancer. 2023;23:206.
PubMed Abstract available

PANG L, Xie M, Ma X, Huang A, et al
Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
BMC Cancer. 2023;23:203.
PubMed Abstract available

SUN H, Ren P, Chen Y, Lan L, et al
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study.
BMC Cancer. 2023;23:198.
PubMed Abstract available

February 2023

CAI JS, Li Y, Wang X
Is prior cancer history a hindrance for non-small cell lung cancer patients to participate in clinical trials?
BMC Cancer. 2023;23:155.
PubMed Abstract available

HSIEH HH, Wu TY, Chen CH, Kuo YH, et al
Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study.
BMC Cancer. 2023;23:151.
PubMed Abstract available

ZHANG J, Wang X, Song C, Li Q, et al
Identification of four metabolic subtypes and key prognostic markers in lung adenocarcinoma based on glycolytic and glutaminolytic pathways.
BMC Cancer. 2023;23:152.
PubMed Abstract available

HUO G, Liu W, Chen P
Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.
BMC Cancer. 2023;23:143.
PubMed Abstract available

DU Z, Zhang F, Liu L, Shen H, et al
LncRNA ANRIL promotes HR repair through regulating PARP1 expression by sponging miR-7-5p in lung cancer.
BMC Cancer. 2023;23:130.
PubMed Abstract available

January 2023

LI J, Li J, Hao H, Lu F, et al
Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma.
BMC Cancer. 2023;23:110.
PubMed Abstract available

ZHANG L, Zhao K, Kuang T, Wang K, et al
The prognostic value of the advanced lung cancer inflammation index in patients with gastrointestinal malignancy.
BMC Cancer. 2023;23:101.
PubMed Abstract available

XU H, Zhu N, Yue Y, Guo Y, et al
Spectral CT-based radiomics signature for distinguishing malignant pulmonary nodules from benign.
BMC Cancer. 2023;23:91.
PubMed Abstract available

DU X, Wen S, Shi R, Xia J, et al
Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study.
BMC Cancer. 2023;23:83.
PubMed Abstract available

PANG LL, Gan JD, Huang YH, Liao J, et al
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.
BMC Cancer. 2023;23:72.
PubMed Abstract available

MORISHIMA T, Kuwabara Y, Saito MK, Odani S, et al
Patterns of staging, treatment, and mortality in gastric, colorectal, and lung cancer among older adults with and without preexisting dementia: a Japanese multicentre cohort study.
BMC Cancer. 2023;23:67.
PubMed Abstract available

DU R, Wang C, Liu J, Wang K, et al
Phosphorylation of TGIF2 represents a therapeutic target that drives EMT and metastasis of lung adenocarcinoma.
BMC Cancer. 2023;23:52.
PubMed Abstract available

ZHANG C, Liang Z, Liu W, Zeng X, et al
Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis.
BMC Cancer. 2023;23:37.
PubMed Abstract available

MERINO SALVADOR M, Fernandez LP, Moreno-Rubio J, Colmenarejo G, et al
Clinical features and lipid metabolism genes as potential biomarkers in advanced lung cancer.
BMC Cancer. 2023;23:36.
PubMed Abstract available

ZHENG Y, Wang L, Niu X, Guo Y, et al
EOAI, a ubiquitin-specific peptidase 5 inhibitor, prevents non-small cell lung cancer progression by inducing DNA damage.
BMC Cancer. 2023;23:28.
PubMed Abstract available

XU J, Zhou H, Luo Z, Chen J, et al
Investigating the functional role of SETD6 in lung adenocarcinoma.
BMC Cancer. 2023;23:18.
PubMed Abstract available

GUAN Y, Gu X, Si J, Xiang J, et al
The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma.
BMC Cancer. 2023;23:16.
PubMed Abstract available

MIURA S, Koh Y, Azuma K, Yoshioka H, et al
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.
BMC Cancer. 2023;23:6.
PubMed Abstract available

December 2022

KIM NY, Park JH, Park J, Kwak N, et al
Effect of chlorhexidine Mouthrinse on prevention of microbial contamination during EBUS-TBNA: a randomized controlled trial.
BMC Cancer. 2022;22:1334.
PubMed Abstract available

PENG D, Liang P, Zhong C, Xu P, et al
Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study.
BMC Cancer. 2022;22:1323.
PubMed Abstract available

YAMAGUCHI O, Atarashi K, Yoshimura K, Shiono A, et al
Establishing a whole blood CD4(+) T cell immunity measurement to predict response to anti-PD-1.
BMC Cancer. 2022;22:1325.
PubMed Abstract available

LO A, McSharry M, Berger AH
Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer.
BMC Cancer. 2022;22:1315.
PubMed Abstract available

FUKUI T, Sasaki J, Igawa S, Kada A, et al
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).
BMC Cancer. 2022;22:1314.
PubMed Abstract available

SHANG K, Huang H, Xu Y, Liu Y, et al
Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation.
BMC Cancer. 2022;22:1295.
PubMed Abstract available

LU G, Li J, Ruan Y, Shi Y, et al
A prognostic nomogram to predict survival in elderly patients with small-cell lung cancer: a large population-based cohort study and external validation.
BMC Cancer. 2022;22:1271.
PubMed Abstract available

FAGHANI A, Guo L, Wright ME, Hughes MC, et al
Construction and case study of a novel lung cancer risk index.
BMC Cancer. 2022;22:1275.
PubMed Abstract available

GUO J, Shen L, Ren Z, Liu Y, et al
Long-term results of postoperative unsuspected small cell lung cancer on real-world data.
BMC Cancer. 2022;22:1256.
PubMed Abstract available

November 2022

SUN B, Hou Q, Liang Y, Xue S, et al
Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer.
BMC Cancer. 2022;22:1233.
PubMed Abstract available

CACCIALANZA R, Cereda E, Agustoni F, Klersy C, et al
Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling.
BMC Cancer. 2022;22:1212.
PubMed Abstract available

LIANG ZR, Ye M, Lv FJ, Fu BJ, et al
Differential diagnosis of benign and malignant patchy ground-glass opacity by thin-section computed tomography.
BMC Cancer. 2022;22:1206.
PubMed Abstract available

GALINDO-UTRERO A, San-Roman-Montero JM, Gil-Prieto R, Gil-de-Miguel A, et al
Trends in hospitalization and in-hospital mortality rates among patients with lung cancer in Spain between 2010 and 2020.
BMC Cancer. 2022;22:1199.
PubMed Abstract available

SINN K, Mosleh B, Grusch M, Klepetko W, et al
Impact of fibrinogen levels and modified Glasgow prognostic score on survival of stage III/N2 non-small cell lung cancer patients treated with neoadjuvant therapy and radical resection.
BMC Cancer. 2022;22:1197.
PubMed Abstract available

XU K, Cai J, Xing J, Li X, et al
Broad-spectrum antibiotics associated gut microbiome disturbance impairs T cell immunity and promotes lung cancer metastasis: a retrospective study.
BMC Cancer. 2022;22:1182.
PubMed Abstract available

KIM N, Jeong D, Jo A, Eum HH, et al
Prescreening of tumor samples for tumor-centric transcriptome analyses of lung adenocarcinoma.
BMC Cancer. 2022;22:1186.
PubMed Abstract available

GENG T, Li M, Chen R, Yang S, et al
Impact of GTF2H1 and RAD54L2 polymorphisms on the risk of lung cancer in the Chinese Han population.
BMC Cancer. 2022;22:1181.
PubMed Abstract available

LIU Y, Gao Y, Wang Y, Zhao C, et al
A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice.
BMC Cancer. 2022;22:1175.
PubMed Abstract available

SATO K, Akamatsu H, Koh Y, Ogawa K, et al
Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes.
BMC Cancer. 2022;22:1148.
PubMed Abstract available

JIANG L, Sun YQ, Brumpton BM, Langhammer A, et al
Body mass index and incidence of lung cancer in the HUNT study: using observational and Mendelian randomization approaches.
BMC Cancer. 2022;22:1152.
PubMed Abstract available

PAN J, Huang Z, Lin H, Cheng W, et al
M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma.
BMC Cancer. 2022;22:1132.
PubMed Abstract available

ASAO T, Watanabe S, Tanaka T, Morita S, et al
A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
BMC Cancer. 2022;22:1135.
PubMed Abstract available

KIM S, Koh J, Song SG, Yim J, et al
High tumor hexokinase-2 expression promotes a pro-tumorigenic immune microenvironment by modulating CD8+/regulatory T-cell infiltration.
BMC Cancer. 2022;22:1120.
PubMed Abstract available

ZHANG R, Wei Y, Shi F, Ren J, et al
The diagnostic and prognostic value of radiomics and deep learning technologies for patients with solid pulmonary nodules in chest CT images.
BMC Cancer. 2022;22:1118.
PubMed Abstract available

October 2022

JIANG Y, Han R, Su J, Fan X, et al
Trends and predictions of lung cancer incidence in Jiangsu Province, China, 2009-2030: a bayesian age-period-cohort modelling study.
BMC Cancer. 2022;22:1110.
PubMed Abstract available

QU L, Tian Y, Wang F, Li Z, et al
NOVA1 promotes NSCLC proliferation and invasion by activating Wnt/beta-catenin signaling.
BMC Cancer. 2022;22:1091.
PubMed Abstract available

ZHANG HY, Xie HL, Ruan GT, Zhang Q, et al
Lymphocyte to C-reactive protein ratio could better predict the prognosis of patients with stage IV cancer.
BMC Cancer. 2022;22:1080.
PubMed Abstract available

LIAO K, Wang T, Coomber-Moore J, Wong DC, et al
Prognostic value of patient-reported outcome measures (PROMs) in adults with non-small cell Lung Cancer: a scoping review.
BMC Cancer. 2022;22:1076.
PubMed Abstract available

KOJIMA K, Imai S, Samejima H, Fujiwara A, et al
PIK3CA mutations associated with a poor postoperative prognosis in patients with pulmonary pleomorphic carcinoma: a retrospective cohort study.
BMC Cancer. 2022;22:1066.
PubMed Abstract available

JI J, Sundquist J, Sundquist K, Zheng G, et al
Familial risk associated with lung cancer as a second primary malignancy in first-degree relatives.
BMC Cancer. 2022;22:1057.
PubMed Abstract available

KUROKAWA K, Mitsuishi Y, Shimada N, Kawakami Y, et al
Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study.
BMC Cancer. 2022;22:1047.
PubMed Abstract available

FUJII H, Nagakura H, Kobayashi N, Kubo S, et al
Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study.
BMC Cancer. 2022;22:1035.
PubMed Abstract available

September 2022

HUA T, Gao Y, Zhang R, Wei Y, et al
Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
BMC Cancer. 2022;22:1022.
PubMed Abstract available

WU H, Ji H, Yang W, Zhang M, et al
Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers.
BMC Cancer. 2022;22:1020.
PubMed Abstract available

CHEN Z, Zhou L, Zhao M, Cao K, et al
Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1-4 brain metastases.
BMC Cancer. 2022;22:1010.
PubMed Abstract available

BOZORGMEHR F, Christopoulos P, Chung I, Cvetkovic J, et al
Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial.
BMC Cancer. 2022;22:1011.
PubMed Abstract available

QIN H, Ke J, Dong S, Li H, et al
Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations.
BMC Cancer. 2022;22:1012.
PubMed Abstract available

RACZKOWSKI L, Pasnik I, Kukielka M, Nicos M, et al
Deep learning-based tumor microenvironment segmentation is predictive of tumor mutations and patient survival in non-small-cell lung cancer.
BMC Cancer. 2022;22:1001.
PubMed Abstract available

HOANG NTD, Hassan G, Suehiro T, Mine Y, et al
BMP and activin membrane-bound inhibitor regulate connective tissue growth factor controlling mesothelioma cell proliferation.
BMC Cancer. 2022;22:984.
PubMed Abstract available

ZHOU L, Zhang Y, Chen W, Niu N, et al
Development and validation of a prognostic nomogram for early stage non-small cell lung cancer: a study based on the SEER database and a Chinese cohort.
BMC Cancer. 2022;22:980.
PubMed Abstract available

MIYAZAKI K, Shiba A, Ikeda T, Higashi Y, et al
Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study.
BMC Cancer. 2022;22:977.
PubMed Abstract available

ISAKA T, Ito H, Yokose T, Saito H, et al
Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
BMC Cancer. 2022;22:966.
PubMed Abstract available

SHIRAISHI Y, Kishimoto J, Shimose T, Toi Y, et al
Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.
BMC Cancer. 2022;22:964.
PubMed Abstract available

SAIFON W, Sensorn I, Trachu N, Oranratnachai S, et al
Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer.
BMC Cancer. 2022;22:963.
PubMed Abstract available

JIANG Y, Xiong Z, Zhao W, Tian D, et al
Pathological components and CT imaging analysis of the area adjacent pleura within the pure ground-glass nodules with pleural deformation in invasive lung adenocarcinoma.
BMC Cancer. 2022;22:958.
PubMed Abstract available

ZHANG Y, Song L, Zeng L, Xiong Y, et al
Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.
BMC Cancer. 2022;22:952.
PubMed Abstract available

MA Y, Li J, Xu X, Zhang Y, et al
The CT delta-radiomics based machine learning approach in evaluating multiple primary lung adenocarcinoma.
BMC Cancer. 2022;22:949.
PubMed Abstract available

August 2022

TREMBECKI L, Sztuder A, Debicka I, Matkowski R, et al
The pilot project of the National Cancer Network in Poland: Assessment of the functioning of the National Cancer Network and results from quality indicators for lung cancer (2019-2021).
BMC Cancer. 2022;22:939.
PubMed Abstract available

XU H, Qi Z, Zhao Q, Xue J, et al
Lentinan enhances the antitumor effects of Delta-like 1 via neutrophils.
BMC Cancer. 2022;22:918.
PubMed Abstract available

MENG Y, Gao J, Wu C, Xie M, et al
The prognosis of different types of pleural tags based on radiologic-pathologic comparison.
BMC Cancer. 2022;22:919.
PubMed Abstract available

CHE H, Xiong Q, Ma J, Chen S, et al
Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
BMC Cancer. 2022;22:904.
PubMed Abstract available

SUN J, Fang F, Olen O, Song M, et al
Normal gastrointestinal mucosa at biopsy and subsequent cancer risk: nationwide population-based, sibling-controlled cohort study.
BMC Cancer. 2022;22:890.
PubMed Abstract available

FAN Y, Dong Y, Sun X, Wang H, et al
Development and validation of MRI-based radiomics signatures as new markers for preoperative assessment of EGFR mutation and subtypes from bone metastases.
BMC Cancer. 2022;22:889.
PubMed Abstract available

ITO H, Date H, Shintani Y, Miyaoka E, et al
The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010.
BMC Cancer. 2022;22:875.
PubMed Abstract available

JIAO Z, Feng X, Cui Y, Wang L, et al
Expression characteristic, immune signature, and prognosis value of EFNA family identified by multi-omics integrative analysis in pan-cancer.
BMC Cancer. 2022;22:871.
PubMed Abstract available

WANG X, Huang Z, Li L, Wang G, et al
DNA damage repair gene signature model for predicting prognosis and chemotherapy outcomes in lung squamous cell carcinoma.
BMC Cancer. 2022;22:866.
PubMed Abstract available

MITCHELL H, Alford BS, O'Hare S, O'Callaghan E, et al
Impact of the COVID-19 pandemic on emergency hospital cancer admissions in a UK region.
BMC Cancer. 2022;22:850.
PubMed Abstract available

July 2022

ZHANG G, Fan J, Yu Z, Chai Y, et al
Video-assisted thoracoscopic treatment as two-day surgery for lung neoplasms: a propensity-matched analysis.
BMC Cancer. 2022;22:832.
PubMed Abstract available

KANG Y, Gan Y, Jiang Y, You J, et al
Cancer-testis antigen KK-LC-1 is a potential biomarker associated with immune cell infiltration in lung adenocarcinoma.
BMC Cancer. 2022;22:834.
PubMed Abstract available

AKGUL S, Chan BA, Manders PM
Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice.
BMC Cancer. 2022;22:829.
PubMed Abstract available

LI B, Jiang C, Xu Y, Fan X, et al
Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer.
BMC Cancer. 2022;22:828.
PubMed Abstract available

LIU Z, Diao Y, Li X
Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors.
BMC Cancer. 2022;22:824.
PubMed Abstract available

LI L, Chen Y, Liao W, Yu Q, et al
Associations of IFT20 and GM130 protein expressions with clinicopathological features and survival of patients with lung adenocarcinoma.
BMC Cancer. 2022;22:809.
PubMed Abstract available

WANG Q, Wang S, Sun Z, Cao M, et al
Evaluation of log odds of positive lymph nodes in predicting the survival of patients with non-small cell lung cancer treated with neoadjuvant therapy and surgery: a SEER cohort-based study.
BMC Cancer. 2022;22:801.
PubMed Abstract available

ZHAO J, Barta JA, McIntire R, Shusted C, et al
Racial difference in BMI and lung cancer diagnosis: analysis of the National Lung Screening Trial.
BMC Cancer. 2022;22:797.
PubMed Abstract available

MATSUMOTO Y, Kawaguchi T, Watanabe M, Isa SI, et al
Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer.
BMC Cancer. 2022;22:775.
PubMed Abstract available

LING Q, Wu S, Liao X, Liu C, et al
Anesthetic propofol enhances cisplatin-sensitivity of non-small cell lung cancer cells through N6-methyladenosine-dependently regulating the miR-486-5p/RAP1-NF-kappaB axis.
BMC Cancer. 2022;22:765.
PubMed Abstract available

FENG H, Cao B, Peng X, Wei Q, et al
Cancer-associated fibroblasts strengthen cell proliferation and EGFR TKIs resistance through aryl hydrocarbon receptor dependent signals in non-small cell lung cancer.
BMC Cancer. 2022;22:764.
PubMed Abstract available

SUN M, Ji H, Xu N, Jiang P, et al
Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
BMC Cancer. 2022;22:762.
PubMed Abstract available

FAIRLEY JA, Cheetham MH, Patton SJ, Rouleau E, et al
Results of a worldwide external quality assessment of cfDNA testing in lung Cancer.
BMC Cancer. 2022;22:759.
PubMed Abstract available

FANG DD, Tao R, Wang G, Li Y, et al
Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
BMC Cancer. 2022;22:752.
PubMed Abstract available

OTSUKA T, Nishida S, Shibahara T, Temizoz B, et al
CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study.
BMC Cancer. 2022;22:744.
PubMed Abstract available

WANG Y, Fang C, Chen R, Yuan S, et al
rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy.
BMC Cancer. 2022;22:741.
PubMed Abstract available

MEI J, Jiang G, Chen Y, Xu Y, et al
HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC.
BMC Cancer. 2022;22:738.
PubMed Abstract available

DUFRAING K, Van Casteren K, Breyne J, D'Haene N, et al
Molecular pathology testing for non-small cell lung cancer: an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders.
BMC Cancer. 2022;22:736.
PubMed Abstract available

PROVENCIO M, Cobo M, Rodriguez-Abreu D, Calvo V, et al
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
BMC Cancer. 2022;22:732.
PubMed Abstract available

June 2022

LIU L, Liu J, Deng X, Tu L, et al
A nomogram based on A-to-I RNA editing predicting overall survival of patients with lung squamous carcinoma.
BMC Cancer. 2022;22:715.
PubMed Abstract available

ZHOU W, Zhang W
A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma.
BMC Cancer. 2022;22:694.
PubMed Abstract available

MOORE A, Bennett B, Taylor-Stokes G, McDonald L, et al
Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.
BMC Cancer. 2022;22:693.
PubMed Abstract available

ZHANG K, Wang K, Zhang C, Teng X, et al
Exploring the potential mechanism of emetine against coronavirus disease 2019 combined with lung adenocarcinoma: bioinformatics and molecular simulation analyses.
BMC Cancer. 2022;22:687.
PubMed Abstract available

YUAN J, Sun Y, Wang K, Wang Z, et al
Development and validation of reassigned CEA, CYFRA21-1 and NSE-based models for lung cancer diagnosis and prognosis prediction.
BMC Cancer. 2022;22:686.
PubMed Abstract available

HAO X, Zhang J, Chen G, Cao W, et al
Aberrant expression of GSTM5 in lung adenocarcinoma is associated with DNA hypermethylation and poor prognosis.
BMC Cancer. 2022;22:685.
PubMed Abstract available

QIU L, Xu Y, Xu H, Yu B, et al
The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis.
BMC Cancer. 2022;22:681.
PubMed Abstract available

ZHANG X, Wang D, Sun T, Li W, et al
Advanced lung cancer inflammation index (ALI) predicts prognosis of patients with gastric cancer after surgical resection.
BMC Cancer. 2022;22:684.
PubMed Abstract available

HUANG WJ, Wang GY, Liu ZY, Zhang ML, et al
Preoperative PDW levels predict pulmonary metastasis in patients with hepatocellular carcinoma.
BMC Cancer. 2022;22:683.
PubMed Abstract available

ZHENG Q, Min S, Zhou Y
A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
BMC Cancer. 2022;22:674.
PubMed Abstract available

GEN S, Tanaka I, Morise M, Koyama J, et al
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
BMC Cancer. 2022;22:654.
PubMed Abstract available

DENG S, Jiang Z, Cao Y, Gu J, et al
Development and validation of a prognostic scoring system for patients with colorectal cancer hepato-pulmonary metastasis: a retrospective study.
BMC Cancer. 2022;22:643.
PubMed Abstract available

CALVET L, Dos-Santos O, Spanakis E, Jean-Baptiste V, et al
YAP1 is essential for malignant mesothelioma tumor maintenance.
BMC Cancer. 2022;22:639.
PubMed Abstract available

JIANG J, Lu Y, Zhang F, Pan T, et al
Semaphorin 4B promotes tumor progression and associates with immune infiltrates in lung adenocarcinoma.
BMC Cancer. 2022;22:632.
PubMed Abstract available

WANG Y, Song W, Zhou S, Chang S, et al
The genomic and transcriptome characteristics of lung adenocarcinoma patients with previous breast cancer.
BMC Cancer. 2022;22:618.
PubMed Abstract available

NOKIHARA H, Ogino H, Mitsuhashi A, Kondo K, et al
Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion.
BMC Cancer. 2022;22:597.
PubMed Abstract available

May 2022

YANG J, Luo G, Li C, Zhao Z, et al
Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma.
BMC Cancer. 2022;22:589.
PubMed Abstract available

TSE LA, Wang F, Wong MC, Au JS, et al
Risk assessment and prediction for lung cancer among Hong Kong Chinese men.
BMC Cancer. 2022;22:585.
PubMed Abstract available

JIN Y, Lin C, Shi X, He Q, et al
Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib.
BMC Cancer. 2022;22:586.
PubMed Abstract available

LEIBOWITZ BD, Dougherty BV, Bell JSK, Kapilivsky J, et al
Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
BMC Cancer. 2022;22:587.
PubMed Abstract available

YANG H, Wen L, Pan Y, Shan C, et al
Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
BMC Cancer. 2022;22:580.
PubMed Abstract available

GU X, Shi Z, Shao L, Zhang Y, et al
Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study.
BMC Cancer. 2022;22:576.
PubMed Abstract available

SHENG H, Hao Z, Zhu L, Zeng Y, et al
Construction and validation of a two-gene signature based on SUMOylation regulatory genes in non-small cell lung cancer patients.
BMC Cancer. 2022;22:572.
PubMed Abstract available

CHEN CL, Wang ST, Liao WC, Chen CH, et al
When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan.
BMC Cancer. 2022;22:571.
PubMed Abstract available

TANG Y, Luo J, Zhou Y, Zang H, et al
Overexpressed p-S6 associates with lymph node metastasis and predicts poor prognosis in non-small cell lung cancer.
BMC Cancer. 2022;22:564.
PubMed Abstract available

CAMINA N, McWilliams TL, McKeon TP, Penning TM, et al
Identification of spatio-temporal clusters of lung cancer cases in Pennsylvania, USA: 2010-2017.
BMC Cancer. 2022;22:555.
PubMed Abstract available

KIM J, You HJ, Youn C
SCARA3 inhibits cell proliferation and EMT through AKT signaling pathway in lung cancer.
BMC Cancer. 2022;22:552.
PubMed Abstract available

UCHIDA Y, Kinose D, Nagatani Y, Tanaka-Mizuno S, et al
Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors.
BMC Cancer. 2022;22:551.
PubMed Abstract available

WANG C, Zhu S, Miao C, Wang Y, et al
Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial.
BMC Cancer. 2022;22:542.
PubMed Abstract available

SONG X, Xie Y, Zhu Y, Lou Y, et al
Is lobectomy superior to sub-lobectomy in non-small cell lung cancer with pleural invasion? A population-based competing risk analysis.
BMC Cancer. 2022;22:541.
PubMed Abstract available

EBERST G, Vernerey D, Laheurte C, Meurisse A, et al
Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer.
BMC Cancer. 2022;22:529.
PubMed Abstract available

TANG S, Ni J, Chen B, Sun F, et al
PAFAH1B3 predicts poor prognosis and promotes progression in lung adenocarcinoma.
BMC Cancer. 2022;22:525.
PubMed Abstract available

XU Z, Liu C, Zhu Y, Zou Z, et al
Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.
BMC Cancer. 2022;22:514.
PubMed Abstract available

TAKADA K, Shimokawa M, Takamori S, Shimamatsu S, et al
A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study.
BMC Cancer. 2022;22:503.
PubMed Abstract available

XU J, Zhi X, Xie L, Sun X, et al
Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy.
BMC Cancer. 2022;22:500.
PubMed Abstract available

DU R, Yang H, Zhou H, Ma L, et al
The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy.
BMC Cancer. 2022;22:491.
PubMed Abstract available

April 2022

RODRIGUES A, Chauhan J, Sagkriotis A, Aasaithambi S, et al
Understanding the lived experience of lung cancer: a European social media listening study.
BMC Cancer. 2022;22:475.
PubMed Abstract available

VIRGILSEN LF, Vedsted P, Falborg AZ, Pedersen AF, et al
Routes to cancer diagnosis for patients with pre-existing psychiatric disorders: a nationwide register-based cohort study.
BMC Cancer. 2022;22:472.
PubMed Abstract available

KAGIMOTO A, Mimura T, Kamigaichi A, Yamashita Y, et al
Prognosis of resected non-small cell lung cancer with pleural plaques on intrathoracic findings.
BMC Cancer. 2022;22:469.
PubMed Abstract available

DHALIWAL I, Kassirian S, Mitchell MA, Qiabi M, et al
Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR).
BMC Cancer. 2022;22:468.
PubMed Abstract available

HYLDGAARD C, Trolle C, Harders SMW, Engberg H, et al
Increased use of diagnostic CT imaging increases the detection of stage IA lung cancer: pathways and patient characteristics.
BMC Cancer. 2022;22:464.
PubMed Abstract available

ZHOU W, Ma J, Meng L, Liu D, et al
Deletion of TRIB3 disrupts the tumor progression induced by integrin alphavbeta3 in lung cancer.
BMC Cancer. 2022;22:459.
PubMed Abstract available

HAN KT, Chang J, Choi DW, Kim S, et al
Association of institutional transition of cancer care with mortality in elderly patients with lung cancer: a retrospective cohort study using national claim data.
BMC Cancer. 2022;22:452.
PubMed Abstract available

JIANG R, Huang J, Sun X, Chu X, et al
Construction of in vitro 3-D model for lung cancer-cell metastasis study.
BMC Cancer. 2022;22:438.
PubMed Abstract available

ZIOLKOWSKA B, Cybulska-Stopa B, Papantoniou D, Suwinski R, et al
Systemic treatment in patients with malignant pleural mesothelioma - real life experience.
BMC Cancer. 2022;22:432.
PubMed Abstract available

MATSUNAGA T, Saito H, Kuroda H, Osaki T, et al
CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab.
BMC Cancer. 2022;22:418.
PubMed Abstract available

ZHANG X, Wu Z, Ma K
SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma.
BMC Cancer. 2022;22:406.
PubMed Abstract available

RANGANATH H, Jain AL, Smith JR, Ryder J, et al
Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
BMC Cancer. 2022;22:407.
PubMed Abstract available

ZHANG Y, Xiao P, Hu X
LINC00511 enhances LUAD malignancy by upregulating GCNT3 via miR-195-5p.
BMC Cancer. 2022;22:389.
PubMed Abstract available

YANG H, Chen H, Zhang G, Li H, et al
Diagnostic value of circulating genetically abnormal cells to support computed tomography for benign and malignant pulmonary nodules.
BMC Cancer. 2022;22:382.
PubMed Abstract available

YAMAMOTO T, Tsukita Y, Katagiri Y, Matsushita H, et al
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice.
BMC Cancer. 2022;22:364.
PubMed Abstract available

March 2022

ZHU GL, Xu C, Yang KB, Tang SQ, et al
Causal relationship between genetically predicted depression and cancer risk: a two-sample bi-directional mendelian randomization.
BMC Cancer. 2022;22:353.
PubMed Abstract available

MIYAWAKI E, Kenmotsu H, Shintani Y, Sekine I, et al
Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study.
BMC Cancer. 2022;22:342.
PubMed Abstract available

ZHAO P, Zhen H, Zhao H, Zhao L, et al
Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
BMC Cancer. 2022;22:328.
PubMed Abstract available

SHIMAMURA SS, Shukuya T, Asao T, Hayakawa D, et al
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?
BMC Cancer. 2022;22:323.
PubMed Abstract available

GUGGENBERGER J, Kenndoff S, Taugner J, Kasmann L, et al
Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab.
BMC Cancer. 2022;22:317.
PubMed Abstract available

ZHANG Y, Wang W, Hu Q, Liang Z, et al
Clinic and genetic similarity assessments of atypical carcinoid, neuroendocrine neoplasm with atypical carcinoid morphology and elevated mitotic count and large cell neuroendocrine carcinoma.
BMC Cancer. 2022;22:321.
PubMed Abstract available

YANG F, Sun Z, Wang D, Du T, et al
MiR-106b-5p regulates esophageal squamous cell carcinoma progression by binding to HPGD.
BMC Cancer. 2022;22:308.
PubMed Abstract available

ZHANG W, Zhang Q, Che L, Xie Z, et al
Using biological information to analyze potential miRNA-mRNA regulatory networks in the plasma of patients with non-small cell lung cancer.
BMC Cancer. 2022;22:299.
PubMed Abstract available

ZHANG B, Shi C, Gao Z, Zhong H, et al
Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
BMC Cancer. 2022;22:294.
PubMed Abstract available

ROJO F, Conde E, Torres H, Cabezon-Gutierrez L, et al
Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.
BMC Cancer. 2022;22:292.
PubMed Abstract available

HESSLER N, Junger ST, Meissner AK, Kocher M, et al
Recurrent brain metastases: the role of resection of in a comprehensive multidisciplinary treatment setting.
BMC Cancer. 2022;22:275.
PubMed Abstract available

LIU S, Tian W, Ma Y, Li J, et al
Serum exosomal proteomics analysis of lung adenocarcinoma to discover new tumor markers.
BMC Cancer. 2022;22:279.
PubMed Abstract available

CARROLL R, Bortolini M, Calleja A, Munro R, et al
Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
BMC Cancer. 2022;22:255.
PubMed Abstract available

HOLMEN OLOFSSON G, Mikkelsen MK, Ragle AM, Christiansen AB, et al
High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI AIM)-a randomized controlled trial.
BMC Cancer. 2022;22:246.
PubMed Abstract available

MIAO H, Ren Q, Li H, Zeng M, et al
Comprehensive analysis of the autophagy-dependent ferroptosis-related gene FANCD2 in lung adenocarcinoma.
BMC Cancer. 2022;22:225.
PubMed Abstract available

February 2022

BOGERE N, Bongomin F, Katende A, Omaido BA, et al
A 10-year retrospective study of lung cancer in Uganda.
BMC Cancer. 2022;22:204.
PubMed Abstract available

ZENG Y, Guo T, Zhou Y, Zhao Y, et al
Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.
BMC Cancer. 2022;22:198.
PubMed Abstract available

WEN S, Peng W, Chen Y, Du X, et al
Four differentially expressed genes can predict prognosis and microenvironment immune infiltration in lung cancer: a study based on data from the GEO.
BMC Cancer. 2022;22:193.
PubMed Abstract available

VIVODA TOMSIC M, Korosec P, Kovac V, Bisdas S, et al
Dynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy.
BMC Cancer. 2022;22:191.
PubMed Abstract available

XU Y, Lin G, Liu Y, Lin X, et al
An integrated analysis of the competing endogenous RNA network associated of prognosis of stage I lung adenocarcinoma.
BMC Cancer. 2022;22:188.
PubMed Abstract available

KANEDA T, Kurata T, Yoshida T, Kibata K, et al
Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer.
BMC Cancer. 2022;22:154.
PubMed Abstract available

SHARMA AL, Meitei PM, Machathoibi TC, Singh NT, et al
Ovarian cancer G protein-coupled receptor 1 inhibits A549 cells migration through casein kinase 2alpha intronless gene and neutral endopeptidase.
BMC Cancer. 2022;22:143.
PubMed Abstract available

STROYAKOVSKIY DL, Fadeeva NV, Matrosova MP, Shelepen KG, et al
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.
BMC Cancer. 2022;22:129.
PubMed Abstract available

January 2022

YAO Q, Yu Y, Wang Z, Zhang M, et al
CANT1 serves as a potential prognostic factor for lung adenocarcinoma and promotes cell proliferation and invasion in vitro.
BMC Cancer. 2022;22:117.
PubMed Abstract available

CHEN W, Guo Z, Wu J, Lin G, et al
Identification of a ZC3H12D-regulated competing endogenous RNA network for prognosis of lung adenocarcinoma at single-cell level.
BMC Cancer. 2022;22:115.
PubMed Abstract available

XIAN H, Li Y, Zou B, Chen Y, et al
Identification of TIMELESS and RORA as key clock molecules of non-small cell lung cancer and the comprehensive analysis.
BMC Cancer. 2022;22:107.
PubMed Abstract available

KOU W, Li B, Shi Y, Zhao Y, et al
High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis.
BMC Cancer. 2022;22:110.
PubMed Abstract available

NYEIN AF, Bari S, Hogue S, Zhao Y, et al
Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer.
BMC Cancer. 2022;22:101.
PubMed Abstract available

THOMPSON NA, Stewart GD, Welsh SJ, Doherty GJ, et al
The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
BMC Cancer. 2022;22:99.
PubMed Abstract available

ZHANG Q, Cai XW, Feng W, Yu W, et al
Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer.
BMC Cancer. 2022;22:96.
PubMed Abstract available

RAN H, Ma J, Cai L, Zhou H, et al
Serum cholinesterase may independently predict prognosis in non-small-cell lung cancer.
BMC Cancer. 2022;22:93.
PubMed Abstract available

TUBIO-PEREZ RA, Torres-Duran M, Garcia-Rodriguez ME, Candal-Pedreira C, et al
Alpha-1 antitrypsin deficiency and risk of lung cancer in never-smokers: a multicentre case-control study.
BMC Cancer. 2022;22:81.
PubMed Abstract available

TUMINELLO S, Alpert N, Veluswamy RR, Kumar A, et al
Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis.
BMC Cancer. 2022;22:80.
PubMed Abstract available

ZHOU Y, Yu T, Zhang Y, Qian L, et al
Comparison of surgical outcomes and prognosis between wedge resection and simple Segmentectomy for GGO diameter between 2 cm and 3 cm in non-small cell lung cancer: a multicenter and propensity score matching analysis.
BMC Cancer. 2022;22:71.
PubMed Abstract available

SHARP J, Prasad V
An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC).
BMC Cancer. 2022;22:70.
PubMed Abstract available

WINTHER-LARSEN A, Aggerholm-Pedersen N, Sandfeld-Paulsen B
Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients.
BMC Cancer. 2022;22:63.
PubMed Abstract available

WESSOLLY M, Stephan-Falkenau S, Streubel A, Wiesweg M, et al
Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy.
BMC Cancer. 2022;22:46.
PubMed Abstract available

VACHENC S, Gobbo J, Moujarrebe SE, Desmoulins I, et al
OncoSNIPE(R) Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients.
BMC Cancer. 2022;22:41.
PubMed Abstract available

December 2021

LIN S, Mo H, Li Y, Guan X, et al
Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population.
BMC Cancer. 2021;21:1330.
PubMed Abstract available

ZHENG Y, Tang L, Liu Z
Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer.
BMC Cancer. 2021;21:1322.
PubMed Abstract available

SUN CY, Shi JF, Fu WQ, Zhang X, et al
Catastrophic health expenditure and its determinants in households with lung cancer patients in China: a retrospective cohort study.
BMC Cancer. 2021;21:1323.
PubMed Abstract available

JIANG S, Huang L, Zhen H, Jin P, et al
Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
BMC Cancer. 2021;21:1308.
PubMed Abstract available

November 2021

MA HC, Liu YH, Ding KL, Liu YF, et al
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
BMC Cancer. 2021;21:1278.
PubMed Abstract available

QU J, Wang L, Jiang M, Wei Z, et al
Survival-associated N(6)-adenosine methyltransferase signatures in lung squamous cell carcinoma and clinical verification.
BMC Cancer. 2021;21:1265.
PubMed Abstract available

CHUANG MC, Yang YH, Hsieh MJ, Lin YC, et al
The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study.
BMC Cancer. 2021;21:1257.
PubMed Abstract available

TREMBECKI L, Sztuder A, Pawlak I, Matkowski R, et al
Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy.
BMC Cancer. 2021;21:1252.
PubMed Abstract available

MIYAWAKI T, Kenmotsu H, Kodama H, Nishioka N, et al
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
BMC Cancer. 2021;21:1247.
PubMed Abstract available

TAKANASHI Y, Funai K, Eto F, Mizuno K, et al
Decreased sphingomyelin (t34:1) is a candidate predictor for lung squamous cell carcinoma recurrence after radical surgery: a case-control study.
BMC Cancer. 2021;21:1232.
PubMed Abstract available

CHEN Z, Yang C, Guo Z, Song S, et al
A novel PDX modeling strategy and its application in metabolomics study for malignant pleural mesothelioma.
BMC Cancer. 2021;21:1235.
PubMed Abstract available

LI J, Liu W, Dong X, Dai Y, et al
The construction and analysis of ceRNA network and patterns of immune infiltration in lung adenocarcinoma.
BMC Cancer. 2021;21:1228.
PubMed Abstract available

WANG Q, Wei S, Li S, Yu J, et al
Comparison of the analgesic effect of ultrasound-guided paravertebral block and ultrasound-guided retrolaminar block in Uniportal video-assisted Thoracoscopic surgery: a prospective, randomized study.
BMC Cancer. 2021;21:1229.
PubMed Abstract available

CHEN YY, Chang SC, Chang CY, Chang CF, et al
Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naive patients.
BMC Cancer. 2021;21:1225.
PubMed Abstract available

PAN H, Pan Z, Guo F, Meng F, et al
MicroRNA-1915-3p inhibits cell migration and invasion by targeting SET in non-small-cell lung cancer.
BMC Cancer. 2021;21:1218.
PubMed Abstract available

BA H, Liu L, Peng Q, Chen J, et al
The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
BMC Cancer. 2021;21:1220.
PubMed Abstract available

WANG Y, Zheng R, Hu P, Zhang Z, et al
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.
BMC Cancer. 2021;21:1215.
PubMed Abstract available

ZHENG Q, Wang Z, Zhang M, Yu Y, et al
Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
BMC Cancer. 2021;21:1216.
PubMed Abstract available

LI J, Lam ASM, Yau STY, Yiu KKL, et al
Antihypertensive treatments and risks of lung Cancer: a large population-based cohort study in Hong Kong.
BMC Cancer. 2021;21:1202.
PubMed Abstract available

HEMMINKI K, Forsti A, Chen T, Hemminki A, et al
Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden.
BMC Cancer. 2021;21:1189.
PubMed Abstract available

October 2021

TONNEAU M, Mouttet-Audouard R, Le Tinier F, Mirabel X, et al
Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review.
BMC Cancer. 2021;21:1168.
PubMed Abstract available

BECA JM, Walsh S, Raza K, Hubay S, et al
Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
BMC Cancer. 2021;21:1162.
PubMed Abstract available

LIU X, Ji W, Zheng K, Lu J, et al
The correlation between skeletal muscle index of the L3 vertebral body and malnutrition in patients with advanced lung cancer.
BMC Cancer. 2021;21:1148.
PubMed Abstract available

LUERKEN L, Thurn PL, Zeman F, Stroszczynski C, et al
Conspicuity of malignant pleural mesothelioma in contrast enhanced MDCT - arterial phase or late phase?
BMC Cancer. 2021;21:1144.
PubMed Abstract available

ZHANG P, Li T, Tao X, Jin X, et al
HRCT features between lepidic-predominant type and other pathological subtypes in early-stage invasive pulmonary adenocarcinoma appearing as a ground-glass nodule.
BMC Cancer. 2021;21:1124.
PubMed Abstract available

UEDA D, Yamamoto A, Shimazaki A, Walston SL, et al
Artificial intelligence-supported lung cancer detection by multi-institutional readers with multi-vendor chest radiographs: a retrospective clinical validation study.
BMC Cancer. 2021;21:1120.
PubMed Abstract available

MIYAWAKI T, Kenmotsu H, Harada H, Ohde Y, et al
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).
BMC Cancer. 2021;21:1121.
PubMed Abstract available

MERINO T, Pinto MP, Orellana MP, Martinez G, et al
Multimodal assessment of acute cardiac toxicity induced by thoracic radiotherapy in cancer patients. Study protocol.
BMC Cancer. 2021;21:1114.
PubMed Abstract available

YANG X, Zhong J, Yu Z, Zhuo M, et al
Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.
BMC Cancer. 2021;21:1107.
PubMed Abstract available

ZHANG Y, Yin X, Wang Q, Song X, et al
A novel gene expression signature-based on B-cell proportion to predict prognosis of patients with lung adenocarcinoma.
BMC Cancer. 2021;21:1098.
PubMed Abstract available

MA W, Liang J, Mo J, Zhang S, et al
Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma.
BMC Cancer. 2021;21:1096.
PubMed Abstract available

BJAANAES MM, Nilsen G, Halvorsen AR, Russnes HG, et al
Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors.
BMC Cancer. 2021;21:1089.
PubMed Abstract available

September 2021

HUANG CC, Lai CY, Tsai CH, Wang JY, et al
Combined effects of cigarette smoking, DNA methyltransferase 3B genetic polymorphism, and DNA damage on lung cancer.
BMC Cancer. 2021;21:1066.
PubMed Abstract available

KIM HS, Kim HJ, Lee MR, Han I, et al
EMMPRIN expression is associated with metastatic progression in osteosarcoma.
BMC Cancer. 2021;21:1059.
PubMed Abstract available

CHENG S, Yang L, Dai X, Wang J, et al
The risk and prognostic factors for brain metastases in esophageal cancer patients: an analysis of the SEER database.
BMC Cancer. 2021;21:1057.
PubMed Abstract available

RODRIGUEZ-ACEVEDO AJ, Chan RJ, Olsen CM, Pandeya N, et al
Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia.
BMC Cancer. 2021;21:1055.
PubMed Abstract available

NIKSIC M, Redondo-Sanchez D, Chang YL, Rodriguez-Barranco M, et al
The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study.
BMC Cancer. 2021;21:1048.
PubMed Abstract available

YANG X, Jin X, Xu R, Yu Z, et al
ER expression associates with poor prognosis in male lung squamous carcinoma after radical resection.
BMC Cancer. 2021;21:1043.
PubMed Abstract available

AI X, Song Z, Jian H, Zhou Z, et al
Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
BMC Cancer. 2021;21:1033.
PubMed Abstract available

LIU J, Yin J, Liu Y, Xu Z, et al
Characteristics of 1270 Chinese sibling pairs with cancer.
BMC Cancer. 2021;21:1027.
PubMed Abstract available

WU LL, Li CW, Lin WK, Qiu LH, et al
Incidence and survival analyses for occult lung cancer between 2004 and 2015: a population-based study.
BMC Cancer. 2021;21:1009.
PubMed Abstract available

JAKOBSEN E, Olsen KE, Bliddal M, Hornbak M, et al
Forecasting lung cancer incidence, mortality, and prevalence to year 2030.
BMC Cancer. 2021;21:985.
PubMed Abstract available

NAKANISHI K, Nakamura S, Sugiyama T, Kadomatsu Y, et al
Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
BMC Cancer. 2021;21:983.
PubMed Abstract available

August 2021

GUTIERREZ L, Royuela A, Carcereny E, Lopez-Castro R, et al
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data.
BMC Cancer. 2021;21:977.
PubMed Abstract available

WANG C, Li J, Zhang Q, Wu J, et al
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
BMC Cancer. 2021;21:968.
PubMed Abstract available

KHALIL AA, Hau E, Gebski V, Grau C, et al
Personal innovative approach in radiation therapy of lung cancer- functional lung avoidance SPECT-guided (ASPECT) radiation therapy: a study protocol for phase II randomised double-blind clinical trial.
BMC Cancer. 2021;21:940.
PubMed Abstract available

LIU T, Wang J, Li T, Cui P, et al
Predicting disease progression in advanced non-small cell lung cancer with circulating neutrophil-derived and platelet-derived microparticles.
BMC Cancer. 2021;21:939.
PubMed Abstract available

ZHOU H, Zheng M, Shi M, Wang J, et al
Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
BMC Cancer. 2021;21:938.
PubMed Abstract available

ZHANG X, Cao Y, Chen L
Construction of a prognostic signature of autophagy-related lncRNAs in non-small-cell lung cancer.
BMC Cancer. 2021;21:921.
PubMed Abstract available

FEIL C, Staib F, Berger MR, Stein T, et al
Sniffer dogs can identify lung cancer patients from breath and urine samples.
BMC Cancer. 2021;21:917.
PubMed Abstract available

CAO L, Jia M, Sun PL, Gao H, et al
Histopathologic features from preoperative biopsies to predict spread through air spaces in early-stage lung adenocarcinoma: a retrospective study.
BMC Cancer. 2021;21:913.
PubMed Abstract available

MUNOZ-MONTANO W, Muniz-Hernandez S, Aviles-Salas A, Catalan R, et al
RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin.
BMC Cancer. 2021;21:892.
PubMed Abstract available

WANG S, Yu Y, Xu W, Lv X, et al
Dynamic nomograms combining N classification with ratio-based nodal classifications to predict long-term survival for patients with lung adenocarcinoma after surgery: a SEER population-based study.
BMC Cancer. 2021;21:653.
PubMed Abstract available

July 2021

YU W, Ye F, Yuan X, Ma Y, et al
A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.
BMC Cancer. 2021;21:877.
PubMed Abstract available

WANG X, Cai J, Zeng Z, Liu A, et al
Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
BMC Cancer. 2021;21:873.
PubMed Abstract available

WU CE, Chang CF, Huang CY, Yang CT, et al
Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study.
BMC Cancer. 2021;21:859.
PubMed Abstract available

GAO L, Zhang L
Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for lung adenocarcinoma.
BMC Cancer. 2021;21:849.
PubMed Abstract available

LAI J, Yang H, Xu T
Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
BMC Cancer. 2021;21:848.
PubMed Abstract available

TANG Y, Zhang R, Li Y, Xu S, et al
Genetic polymorphisms and haplotypes of ERCC1 and ERCC2 associated with quality of life, depression, and anxiety status among patients with lung cancer.
BMC Cancer. 2021;21:842.
PubMed Abstract available

LUO H, Zhang Y, Qin G, Jiang B, et al
LncRNA MCM3AP-AS1 sponges miR-148a to enhance cell invasion and migration in small cell lung cancer.
BMC Cancer. 2021;21:820.
PubMed Abstract available

HUNG A, Lee KM, Lynch JA, Li Y, et al
Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer.
BMC Cancer. 2021;21:824.
PubMed Abstract available

SHEN H, Deng G, Chen Q, Qian J, et al
The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database.
BMC Cancer. 2021;21:825.
PubMed Abstract available

CHAU J, Yadav M, Liu B, Furqan M, et al
Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.
BMC Cancer. 2021;21:808.
PubMed Abstract available

PARK K, Kim JS, Kim JH, Kim YC, et al
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.
BMC Cancer. 2021;21:802.
PubMed Abstract available

PASCOE J, Jackson A, Gaskell C, Gaunt C, et al
Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH).
BMC Cancer. 2021;21:800.
PubMed Abstract available

WANG X, Zhou B, Xia Y, Zuo J, et al
A methylation-based nomogram for predicting survival in patients with lung adenocarcinoma.
BMC Cancer. 2021;21:801.
PubMed Abstract available

CHENG L, Han T, Chen B, Nie K, et al
TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma.
BMC Cancer. 2021;21:794.
PubMed Abstract available

LIU T, Luo H, Zhang J, Hu X, et al
Molecular identification of an immunity- and Ferroptosis-related gene signature in non-small cell lung Cancer.
BMC Cancer. 2021;21:783.
PubMed Abstract available

CHEN Z, Wei J, Li M, Zhao Y, et al
A circular RNAs dataset landscape reveals potential signatures for the detection and prognosis of early-stage lung adenocarcinoma.
BMC Cancer. 2021;21:781.
PubMed Abstract available

SARACINO L, Bortolotto C, Tomaselli S, Fraolini E, et al
Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study.
BMC Cancer. 2021;21:762.
PubMed Abstract available

June 2021

HUANG J, Hu M, Niu H, Wang J, et al
Osteopontin isoform c promotes the survival of cisplatin-treated NSCLC cells involving NFATc2-mediated suppression on calcium-induced ROS levels.
BMC Cancer. 2021;21:750.
PubMed Abstract available

YANG X, Zheng Y, Han Z, Zhang X, et al
Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy.
BMC Cancer. 2021;21:752.
PubMed Abstract available

CHRISTOPOULOS P, Bozorgmehr F, Bruckner L, Chung I, et al
Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
BMC Cancer. 2021;21:743.
PubMed Abstract available

CHEN J, Mao J, Ma N, Wu KL, et al
Definitive carbon ion radiotherapy for tracheobronchial adenoid cystic carcinoma: a preliminary report.
BMC Cancer. 2021;21:734.
PubMed Abstract available

JANG YJ, Hyun DG, Choi CM, Lee DH, et al
Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung.
BMC Cancer. 2021;21:731.
PubMed Abstract available

XIA Q, Chen G, Ren Y, Zheng T, et al
Investigating efficacy of "microbiota modulation of the gut-lung Axis" combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial.
BMC Cancer. 2021;21:721.
PubMed Abstract available

RUSMAULLY J, Tvardik N, Martin D, Billmann R, et al
Risk of lung cancer among women in relation to lifetime history of tobacco smoking: a population-based case-control study in France (the WELCA study).
BMC Cancer. 2021;21:711.
PubMed Abstract available

ZENG H, Yang Z, Li J, Wen Y, et al
Associations between female lung cancer risk and sex steroid hormones: a systematic review and meta-analysis of the worldwide epidemiological evidence on endogenous and exogenous sex steroid hormones.
BMC Cancer. 2021;21:690.
PubMed Abstract available

NADAL E, Bautista D, Cabezon-Gutierrez L, Ortega AL, et al
Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
BMC Cancer. 2021;21:689.
PubMed Abstract available

ZHOU H, Li J, Chen Z, Chen Y, et al
Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis.
BMC Cancer. 2021;21:678.
PubMed Abstract available

CHEN C, Wu Z, Wu Z, Wu C, et al
Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database.
BMC Cancer. 2021;21:666.
PubMed Abstract available

May 2021

HUANG A, Xu Y, Zang X, Wu C, et al
Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
BMC Cancer. 2021;21:634.
PubMed Abstract available

SHAN Q, Shi J, Wang X, Guo J, et al
A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study.
BMC Cancer. 2021;21:640.
PubMed Abstract available

SHARMA V, Sharma A, Raina V, Dabkara D, et al
Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center.
BMC Cancer. 2021;21:630.
PubMed Abstract available

HUANG G, Zhang J, Gong L, Huang Y, et al
A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma.
BMC Cancer. 2021;21:626.
PubMed Abstract available

GUO X, Ma W, Wu H, Xu Y, et al
Synchronous bone metastasis in lung cancer: retrospective study of a single center of 15,716 patients from Tianjin, China.
BMC Cancer. 2021;21:613.
PubMed Abstract available

LU M, Fan X, Liao W, Li Y, et al
Identification of significant genes as prognostic markers and potential tumor suppressors in lung adenocarcinoma via bioinformatical analysis.
BMC Cancer. 2021;21:616.
PubMed Abstract available

CHEN C, Tang Y, Qu WD, Han X, et al
Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics.
BMC Cancer. 2021;21:619.
PubMed Abstract available

WANG Q, Gao W, Gao F, Jin S, et al
Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.
BMC Cancer. 2021;21:602.
PubMed Abstract available

WANG B, Wang S, Ren W
Development and validation of a nomogram to predict survival outcome among epithelial ovarian cancer patients with site-distant metastases: a population-based study.
BMC Cancer. 2021;21:609.
PubMed Abstract available

HEMMINKI K, Forsti A, Hemminki A, Ljungberg B, et al
Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor.
BMC Cancer. 2021;21:604.
PubMed Abstract available

MATSUMOTO A, Nakashima C, Kimura S, Sueoka E, et al
ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies.
BMC Cancer. 2021;21:584.
PubMed Abstract available

JARRY U, Bostoen M, Pineau R, Chaillot L, et al
Correction to: Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.
BMC Cancer. 2021;21:574.
PubMed

GO SI, Park MJ, Lee GW
Clinical significance of the cachexia index in patients with small cell lung cancer.
BMC Cancer. 2021;21:563.
PubMed Abstract available

ZHU D, Ding R, Ma Y, Chen Z, et al
Comorbidity in lung cancer patients and its association with hospital readmission and fatality in China.
BMC Cancer. 2021;21:557.
PubMed Abstract available

GARGIULO P, Arenare L, Gridelli C, Morabito A, et al
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials.
BMC Cancer. 2021;21:549.
PubMed Abstract available

LEVITSKY A, Bernhardson BM, Henoch I, Olin M, et al
Using patients' own knowledge of early sensations and symptoms to develop an interactive, individualized e-questionnaire to facilitate early diagnosis of lung cancer.
BMC Cancer. 2021;21:544.
PubMed Abstract available

YIN P, Yue B, Zhang J, Liu D, et al
Optimal margins for early stage peripheral lung adenocarcinoma resection.
BMC Cancer. 2021;21:533.
PubMed Abstract available

JARRY U, Bostoen M, Pineau R, Chaillot L, et al
Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.
BMC Cancer. 2021;21:530.
PubMed Abstract available

LESTER J, Escriu C, Khan S, Hudson E, et al
Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom.
BMC Cancer. 2021;21:515.
PubMed Abstract available

ZHU L, Zou C, Zhang Z, Wang J, et al
Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.
BMC Cancer. 2021;21:511.
PubMed Abstract available

OKUMURA N, Soh J, Suzuki H, Nakata M, et al
Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301.
BMC Cancer. 2021;21:506.
PubMed Abstract available

ZUO T, Lin W, Liu F, Xu J, et al
Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum.
BMC Cancer. 2021;21:505.
PubMed Abstract available

MA J, Li X, Zhao S, Wang J, et al
Robot-assisted thoracic surgery versus video-assisted thoracic surgery for lung lobectomy or segmentectomy in patients with non-small cell lung cancer: a meta-analysis.
BMC Cancer. 2021;21:498.
PubMed Abstract available

WANG C, Hu K, Deng L, He W, et al
Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.
BMC Cancer. 2021;21:491.
PubMed Abstract available

CHEN YC, Tsai MJ, Lee MH, Kuo CY, et al
Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations.
BMC Cancer. 2021;21:495.
PubMed Abstract available

KRIEGSMANN K, Zgorzelski C, Muley T, Christopoulos P, et al
Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples.
BMC Cancer. 2021;21:486.
PubMed Abstract available

April 2021

WANG X, Zeng Z, Cai J, Xu P, et al
Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.
BMC Cancer. 2021;21:482.
PubMed Abstract available

YAMAMURA J, Kamigaki S, Fujita J, Osato H, et al
New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
BMC Cancer. 2021;21:476.
PubMed Abstract available

KAWAGUCHI Y, Hanaoka J, Ohshio Y, Okamoto K, et al
Locoregional recurrence via mucus-mediated extension following lung resection for mucinous tumors.
BMC Cancer. 2021;21:470.
PubMed Abstract available

YU Y, Ren K
Five long non-coding RNAs establish a prognostic nomogram and construct a competing endogenous RNA network in the progression of non-small cell lung cancer.
BMC Cancer. 2021;21:457.
PubMed Abstract available

HU J, Chen Y, Zhu X, Ma Q, et al
Surgical choice of non-small cell lung cancer with unexpected pleural dissemination intraoperatively.
BMC Cancer. 2021;21:445.
PubMed Abstract available

AYERS KL, Ma M, Debussche G, Corrigan D, et al
A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
BMC Cancer. 2021;21:441.
PubMed Abstract available

HUANG LT, Cao R, Wang YR, Sun L, et al
Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of ran
BMC Cancer. 2021;21:426.
PubMed Abstract available

ZHANG Y, Simoff MJ, Ost D, Wagner OJ, et al
Understanding the patient journey to diagnosis of lung cancer.
BMC Cancer. 2021;21:402.
PubMed Abstract available

JOHNSON MK, Wu S, Pankratz DG, Fedorowicz G, et al
Analytical validation of the Percepta genomic sequencing classifier; an RNA next generation sequencing assay for the assessment of Lung Cancer risk of suspicious pulmonary nodules.
BMC Cancer. 2021;21:400.
PubMed Abstract available

STORK T, Boemans R, Hardes J, Streitburger A, et al
Number of metastases and their response to chemotherapy impact survival of patients with isolated lung metastases from bone-derived sarcoma.
BMC Cancer. 2021;21:375.
PubMed Abstract available

HUANG YS, Chen JL, Chen HM, Yeh LH, et al
Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer.
BMC Cancer. 2021;21:348.
PubMed Abstract available

HOSOYA K, Fujimoto D, Morimoto T, Kumagai T, et al
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
BMC Cancer. 2021;21:346.
PubMed Abstract available

BADE BC, Gan G, Li F, Lu L, et al
"Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study".
BMC Cancer. 2021;21:352.
PubMed Abstract available

March 2021

MIYANAGA A, Matsumoto M, Beck JA, Horikawa I, et al
EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells.
BMC Cancer. 2021;21:310.
PubMed Abstract available

SATO A, Matsubayashi K, Morishima T, Nakata K, et al
Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study.
BMC Cancer. 2021;21:264.
PubMed Abstract available

XING W, Sun H, Yan C, Zhao C, et al
A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
BMC Cancer. 2021;21:263.
PubMed Abstract available

ZHAO Y, Gao Y, Xu X, Zhou J, et al
Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
BMC Cancer. 2021;21:257.
PubMed Abstract available

LI Y, Zhao X, Xiao H, Yang B, et al
APE1 may influence CD4+ naive T cells on recurrence free survival in early stage NSCLC.
BMC Cancer. 2021;21:233.
PubMed Abstract available

WONG SK, Hamm J, Shokoohi A, McGahan CE, et al
Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment.
BMC Cancer. 2021;21:215.
PubMed Abstract available

ZHAI Y, Zhao B, Wang Y, Li L, et al
Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
BMC Cancer. 2021;21:213.
PubMed Abstract available

February 2021

ZHU D, Cao D, Shen M, Lv J, et al
Morphological and genetic heterogeneity of synchronous multifocal lung adenocarcinoma in a Chinese cohort.
BMC Cancer. 2021;21:176.
PubMed Abstract available

WANG Y, Liu J, Huang C, Zeng Y, et al
Development and validation of a nomogram for predicting survival of pulmonary invasive mucinous adenocarcinoma based on surveillance, epidemiology, and end results (SEER) database.
BMC Cancer. 2021;21:148.
PubMed Abstract available

HE Y, Zhao F, Han Q, Zhou Y, et al
Prognostic nomogram for predicting long-term cancer-specific survival in patients with lung carcinoid tumors.
BMC Cancer. 2021;21:141.
PubMed Abstract available

HE X, You J, Ding H, Zhang Z, et al
Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status.
BMC Cancer. 2021;21:132.
PubMed Abstract available

YANG K, Wu Y
A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
BMC Cancer. 2021;21:128.
PubMed Abstract available

January 2021

LI XS, Nie KC, Zheng ZH, Zhou RS, et al
Molecular subtypes based on DNA methylation predict prognosis in lung squamous cell carcinoma.
BMC Cancer. 2021;21:96.
PubMed Abstract available

OYA Y, Yoshida T, Asada K, Oguri T, et al
Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
BMC Cancer. 2021;21:57.
PubMed Abstract available

PARK S, Lee SY, Kim D, Sim YS, et al
Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
BMC Cancer. 2021;21:52.
PubMed Abstract available

December 2020

COLLINS DC, Sundar R, Constantinidou A, Dolling D, et al
Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
BMC Cancer. 2020;20:1210.
PubMed Abstract available

November 2020

KIM MY, Shin JY, Kim JO, Son KH, et al
Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma.
BMC Cancer. 2020;20:1057.
PubMed Abstract available

October 2020

WANG B, Xu L, Li Q, Man S, et al
Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies.
BMC Cancer. 2020;20:1021.
PubMed Abstract available

YAMAMOTO T, Niibe Y, Aoki M, Shintani T, et al
Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival.
BMC Cancer. 2020;20:997.
PubMed Abstract available

September 2020

BILGUUN EO, Kaira K, Kawabata-Iwakawa R, Rokudai S, et al
Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine.
BMC Cancer. 2020;20:935.
PubMed Abstract available

SHINODA Y, Kobayashi E, Kobayashi H, Mori T, et al
Prognostic factors of metastatic myxoid liposarcoma.
BMC Cancer. 2020;20:883.
PubMed Abstract available

ARRIETA O, Catalan R, Guzman-Vazquez S, Barron F, et al
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
BMC Cancer. 2020;20:829.
PubMed Abstract available

August 2020

SAURABH K, Shah PP, Doll MA, Siskind LJ, et al
UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target.
BMC Cancer. 2020;20:824.
PubMed Abstract available

BU X, Liu J, Wei L, Wang X, et al
Epidemiological features and survival outcomes in patients with malignant pulmonary blastoma: a US population-based analysis.
BMC Cancer. 2020;20:811.
PubMed Abstract available

DUAN H, Liang L, Xie S, Wang C, et al
The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.
BMC Cancer. 2020;20:809.
PubMed Abstract available

BOZORGMEHR F, Chung I, Christopoulos P, Krisam J, et al
Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
BMC Cancer. 2020;20:806.
PubMed Abstract available

LIANG J, Li J, Li Z, Meng T, et al
Differentiating the lung lesions using Intravoxel incoherent motion diffusion-weighted imaging: a meta-analysis.
BMC Cancer. 2020;20:799.
PubMed Abstract available

TAKANASHI Y, Funai K, Sato S, Kawase A, et al
Sphingomyelin(d35:1) as a novel predictor for lung adenocarcinoma recurrence after a radical surgery: a case-control study.
BMC Cancer. 2020;20:800.
PubMed Abstract available

JIANG H, Xu S, Chen C
A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
BMC Cancer. 2020;20:782.
PubMed Abstract available

ZHONG L, Xie L, Yang Z, Li L, et al
Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.
BMC Cancer. 2020;20:766.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: